1 June 2017 in Journal of Infection
GPGabriele Peyerl-Hoffmann
+3
20 October 2016 in BMC Infectious Diseases
Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12 and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis. In large multicenter, prospective trials assessing efficacy and safety of ustekinumab increased rates of severe infections have not been observed so far. Here, we report the case of a 64-year old woman presenting with chills, pain and swelling of her right foot with dark maculae at the sole, and elevated inflammatory markers. She had received a third dose of ustekinumab due to psoriatic arthritis three days before admission. Blood cultures revealed growth of Staphylococcus aureus and imaging showed a thickening of the aortic wall ventral the bifurcation above the right internal iliac artery, resembling an acute bacterial endarteritis. Without the evidence of aneurysms and in absence of foreign bodies, the decision for conservative management was made. The patient received four weeks of antibiotic therapy with intravenous flucloxacillin, followed by an oral regime with levofloxacin and rifampicin for an additional four weeks. Inflammatory markers resolved promptly and the patient was discharged in good health. To our knowledge, this is the first report of a severe S. aureus infection in a patient receiving ustekinumab. Albeit ustekinumab is generally regarded as a safe drug, severe bacterial infections should always be included in the differential diagnosis of elevated inflammatory markers in patients receiving biologicals as these might present with nonspecific symptoms and fever might be absent. Any effort to detect deep-seated or metastatic infections should be made to prevent complications and to secure appropriate treatment. Although other risk factors for an invasive staphylococcal infection like psoriasis, recent corticosteroid injection, or prior hospitalisations were present, and therefore a directive causative link between the S. aureus bacteraemia and ustekinumab can not be drawn, we considered the reporting of this case worthwhile to alert clinicians as we believe that ongoing pharmacovigilance to detect increased risks for rare but severe infections beyond phase II and phase III trials in patients treated with biologicals is essential.
1 September 2020 in Journal of Investigative Dermatology
20 January 2026 in Infection
Purpose: Penicillin allergy (PA) delabeling optimizes antibiotic prescribing and is a recognized antimicrobial stewardship (AMS) tool. We aimed to characterize current practices and knowledge of PA delabeling in German non-allergist healthcare professionals to define barriers and facilitators for a wider implementation of delabeling strategies. Methods: A nationwide web-based, anonymous survey was distributed to physicians and hospital pharmacists. It covered four domains: demographics, access to AMS, allergy assessment and attitude towards PA delabeling. Responses were analysed using descriptive and inferential statistics. Results: A total of 504 responses (249 physicians, 255 pharmacists) were analysed. While 86% of respondents were familiar with the concept of delabeling, only 32% had ever performed it, mostly fewer than 6 times in the past year. 12% of physicians regularly took extended allergy histories, and just 2% always used a standardized method. Only ~ 30% of respondents had onsite access to allergy services. Barriers included lack of time, experience and guidance. Pharmacists frequently cited PA management as outside their role. Despite limited experience, 88% of physicians and 71% of pharmacists expressed interest in delabeling if supported by clear algorithms and institutional support. Conclusion: PA delabeling by non-allergists is of great relevance to physicians and pharmacists in Germany but not routinely integrated in clinical pathways, due to missing guidelines, limited resources and unclear role definitions. However, the results of this study highlight the considerable strong potential for implementing structured delabeling strategies—if they are supported by adequate training, clear protocols and sufficiently resourced antimicrobial stewardship teams.
11 May 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Objective: Irrational antibiotic consumption contributes to antimicrobial resistance, adverse effects, and rising costs. Antimicrobial Stewardship (AMS) supports rational antibiotic use through restrictive and supportive measures. In oral and maxillofacial surgery (OMFS), antibiotic consumption is consistently high, and evidence-based guidelines are often lacking. We evaluated a multimodal AMS intervention on antibiotic use in an OMFS department. Design: Before–after study. Setting: OMFS department of a German university hospital. Patients: Hospitalized patients treated in the OMFS department. Intervention: For 12 months, the AMS team conducted weekly ward visits, providing recommendations regarding antibiotic therapy and surgical antibiotic prophylaxis (SAP). In parallel, a mandatory consensus guideline covering these aspects was developed and implemented. Antibiotic use, prevalence, duration of therapy, and SAP before, during, and after the intervention were evaluated; clinical outcomes were not assessed. Results: Pre-intervention, over 70% of patients received antibiotics. Median duration of antibiotic therapy and SAP was 12 and 9 days, respectively. Antibiotic consumption reached 63.8 defined daily dosages per 100 patient days, exceeding national values (median 40.1). During the intervention, antibiotic prevalence decreased below 50% and the duration of antibiotic therapy and SAP was shortened to 9 and 3 days, respectively. Antibiotic consumption decreased by 26% whereas national values increased by nearly 50%. After weekly consultations ceased, antibiotic use rose again but remained below national levels. Conclusions: Antibiotic consumption is high in OMFS. Regular AMS support including consensus guidelines can reduce antibiotic use substantially and sustainably. However, clinical outcomes need to be correlated and adequately staffed AMS teams are needed.